DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahi, J.
Right arrow Articles by Thomas, V. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahi, J.
Right arrow Articles by Thomas, V. H.

Vol. 30, Issue 2, 135-140, February 2002

The Effect of Bergamottin on Diazepam Plasma Levels and P450 Enzymes in Beagle Dogs

Jasminder Sahi, Eric L. Reyner, Jonathan N. Bauman, Kristina Gueneva-Boucheva, James E. Burleigh, and V. Hayden Thomas

Pfizer Global Research and Development, Ann Arbor, Michigan

Bergamottin, a furanocoumarin isolated from grapefruit juice, was investigated for the ability to increase diazepam bioavailability and for its effect on cytochrome P450 (P450) enzymes in the beagle dog liver and intestine. To study the effect of bergamottin on diazepam pharmacokinetics, male beagle dogs were dosed with bergamottin (1 mg/kg) p.o. 0 or 2 h before p.o. diazepam (10 mg). In a second experiment, bergamottin (0.1 mg/kg) was dosed i.v. or p.o. 1 h before p.o. diazepam (10 mg). Plasma samples were collected over 24 h postdose, analyzed by liquid chromatography/mass tandem spectrometry, and diazepam pharmacokinetic parameters were determined. To study the effect of bergamottin on P450 enzymes, beagle dog liver and jejunum was harvested after a 10-day dosing regimen of bergamottin (1 mg/kg) p.o. per day; microsomes were prepared and analyzed for CYP3A12, CYP2B11, CYP1A1/2, and tolbutamide hydroxylase activity. Bergamottin predosing increased the plasma levels of diazepam as observed by Cmax (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC(0-TLDC)] (247.69 versus 2.79 ng · hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition. Diazepam plasma concentrations were increased to a similar level in the presence of i.v. and p.o. administered bergamottin. In hepatic microsomes, bergamottin treatment for 10 days reduced the activity of CYP3A12 by 50% and CYP1A1/2 by 75%. Tolbutamide hydroxylase activity did not change, and CYP2B11 activity was moderately induced. In jejunal microsomes, CYP3A12 activity doubled with bergamottin treatment. CYP2B11, CYP1A1/2 activity and tolbutamide hydroxylation was not detected. In conclusion, bergamottin is both an inhibitor and an inducer of P450 enzymes.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
F. Qiu, R. Zhang, J. Sun, J. A, H. Hao, Y. Peng, H. Ai, and G. Wang
Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes
Drug Metab. Dispos., July 1, 2008; 36(7): 1308 - 1314.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. F Paine, W. W Widmer, S. N Pusek, K. L Beavers, A. B Criss, J. Snyder, and P. B Watkins
Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine
Am. J. Clinical Nutrition, April 1, 2008; 87(4): 863 - 871.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
J. Tibbitts
Issues Related to the Use of Canines in Toxicologic Pathology--Issues With Pharmacokinetics and Metabolism
Toxicol Pathol, January 1, 2003; 31(1_suppl): 17 - 24.
[Abstract] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. H. Wen, J. Sahi, E. Urda, S. Kulkarni, K. Rose, X. Zheng, J. F. Sinclair, H. Cai, S. C. Strom, and V. E. Kostrubsky
Effects of Bergamottin on Human and Monkey Drug-Metabolizing Enzymes in Primary Cultured Hepatocytes
Drug Metab. Dispos., September 1, 2002; 30(9): 977 - 984.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.